digestive system disease
Conditions
Interventions
group 1 :4-6 hours before the examination, dissolve 50g magnesium sulfate in 100ml warm water, take orally at one time, and then drink 2000ml of water within 1 hour
group 2:At 16:00 the day before the examination, 20g magnesium sulfate was dissolved in 100ml warm water, taken orally at one time, and 700ml of water was drunk within 1 hour
4 to 6 hours before colonoscopy, dissolve 50g magnesium sulfate in 100ml warm water, take one time, then drink 2000ml of water within 1 hour
group 3:At 16:00 two days before the examination, 20g magnesium sulfate was dissolved in 100ml warm water, taken orally at one time, and 700ml of water was drunk within 1 hour
At 16:00 the day before the colonoscopy, 20g magnesium sulfate was also dissolved in 100ml warm water, taken orally at one time, then 700ml of water was taken within 1 hour
4-6 hours before colonoscopy, dissolve 50g magnesium sulfate in 100ml warm water, take one time, and then drink 2000ml of water for 1 hour
control group:Patients undergoing intestinal preparation using other methods, including polyethylene glycol, mannitol, simethicone, senna, oral rehydration salts, and some heavy Chinese medicines, eit
Sponsors
Chinese PLA General Hosptial
Eligibility
Sex/Gender
All
Age
10 Years to 80 Years
Inclusion criteria
Inclusion criteria: The inclusion criteria for this study are as follows: 1.Patients with an indication for colonoscopy. 2.Subjects who are medically stable and able to tolerate the colonoscopy procedure. 3.Age range between 10 and 80 years, regardless of gende. 4.Normal levels of blood potassium, sodium, chloride, calcium, and magnesium prior to oral administration of magnesium sulfate. 5.Voluntary participation in the study and signing of an informed consent form.
Exclusion criteria
Exclusion criteria: The exclusion criteria for this study are as follows: 1.Confirmed or suspected cases of gastrointestinal obstruction or perforation, gastric retention, active inflammatory bowel disease or toxic megacolon, acute corrosive esophageal and gastric injury, abdominal aortic aneurysm, acute peritonitis, ulcerative colitis, chronic pelvic inflammatory disease, intestinal luminal stenosis due to intra-abdominal adhesions, or acute life-threatening conditions such as intestinal perforation. 2.Patients with severe cardiac conditions (severe arrhythmias, acute myocardial infarction, severe heart failure, hypertrophic cardiomyopathy), those with cardiac replacement devices, severe pulmonary diseases (e.g., exacerbation of bronchial asthma, respiratory failure), severe renal dysfunction, or individuals with impaired consciousness. 3.Patients with advanced malignant tumors, those who have undergone ileostomy or other structural alterations of the intestines. 4.Pregnant women, lactating women, or women of reproductive age planning pregnancy. 5.Patients with a documented hypersensitivity or allergy to magnesium sulfate. 6.Patients with abnormal levels of blood potassium, sodium, chloride, calcium, or magnesium prior to oral administration of magnesium sulfate. 7.Patients who refuse to undergo colonoscopy. Note: This study is a randomized controlled trial, and the aforementioned exclusion criteria essentially represent clinical judgments of patients who are deemed unable to tolerate or refuse to undergo colonoscopy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the Boston bowel preparation scale,BBPS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum kalium;serum sodium;serum chlorine;serum calcium;serum magnesium;BBPS scores of each segment of colon;Qualification rate of intestinal preparation;Cecal insertion rate;Detection rate of lesions;Intestinal preparation time;Number of bowel movements before examination;Adverse reaction rate;Drug compliance; | — |
Countries
China
Contacts
Public ContactNingli Chai
Chinese PLA General Hosptial
Outcome results
None listed